IQVIA Holdings (IQV) Stock News

IQVIA introduced IQVIA Life Science Models, a suite of AI models built with NVIDIA Nemotron and AWS to predict clinical trial outcomes. Initial evaluation showed 85% prediction accuracy across 50 trials.

IQVIA (IQV) unveiled IQVIA Explorer at TechIQ 2026, a platform that turns complex analytics into near real-time commercial intelligence. Users can analyze treatment starts, switching, and discontinuation in under 15 minutes versus weeks. The tool also helps identify resource opportunities and test assumptions quickly. The launch addresses margin compression and volatility in life sciences.

IQVIA completed a $2 billion offering of 6.375% senior notes due 2034. Net proceeds will redeem its 5.000% notes due 2026, repay a portion of its revolving credit facility, and pay offering expenses. The notes are unsecured obligations of IQVIA Inc., a wholly owned subsidiary.